PharmaBlock Sciences (Nanjing) (300725) Fundamentals 2026 — P/E 43.1x, Revenue Analysis | SniperIQ
PharmaBlock Sciences (Nanjing) (300725) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥7.9B, trading at ¥39.24 on the SHZ. This SniperIQ fundamentals page covers PharmaBlock Sciences (Nanjing)'s valuation (P/E 43.1x, P/B 1.7x), profitability (net margin 9.7%), revenue (¥2.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is PharmaBlock Sciences (Nanjing)'s market cap?
PharmaBlock Sciences (Nanjing) (300725) has a market capitalization of approximately ¥7.9B, trading at ¥39.24 on the SHZ. Market cap moves with the live share price.
What is PharmaBlock Sciences (Nanjing)'s P/E ratio?
PharmaBlock Sciences (Nanjing)'s trailing twelve-month P/E ratio is 43.1x, with a price-to-book (P/B) of 1.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is PharmaBlock Sciences (Nanjing)?
PharmaBlock Sciences (Nanjing) runs a net profit margin of 9.7%, a gross margin of 30.6%, and an operating margin of 10.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does PharmaBlock Sciences (Nanjing) generate?
PharmaBlock Sciences (Nanjing) reported revenue of ¥2.0B for fiscal year 2025, with net income of ¥184M and earnings per share (EPS) of 0.88. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does PharmaBlock Sciences (Nanjing) pay a dividend?
PharmaBlock Sciences (Nanjing) offers a trailing dividend yield of about 0.7%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is PharmaBlock Sciences (Nanjing) financially healthy?
PharmaBlock Sciences (Nanjing) carries a debt-to-equity ratio of 0.03x and a current ratio of 4.23x, with a market beta of 0.55. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is PharmaBlock Sciences (Nanjing) a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For PharmaBlock Sciences (Nanjing) (300725) the key facts are: market cap ¥7.9B, P/E 43.1x, revenue ¥2.0B, 52-week range 30.9-53.54. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track PharmaBlock Sciences (Nanjing)'s full fundamentals live
Get PharmaBlock Sciences (Nanjing)'s 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.